Get the Stockscreener App
1.45
0.68%
-0.01
After Hours:
1.46
0.01
+0.69%
Protalix BioTherapeutics Inc. stock is traded at $1.45, with a volume of 357.10K.
It is down -0.68% in the last 24 hours and down -2.03% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$1.46
Open:
$1.43
24h Volume:
357.10K
Relative Volume:
0.35
Market Cap:
$115.43M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
29.00
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
-3.97%
1M Performance:
-2.03%
6M Performance:
-40.33%
1Y Performance:
+36.79%
1-Day Range:
$1.4104
$1.475
1-Week Range:
$1.4104
$1.53
52-Week Range:
$0.8214
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.45 | 116.23M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
Key metrics from Protalix BioTherapeutics Inc.’s quarterly dataReal-Time Equity Price Action Analysis - Newser
Protalix Lawsuit Dismissed After Bylaws Amendment - TipRanks
What is Protalix BioTherapeutics Inc. company’s growth strategyBeginner Investor Data Feed For Every Investor - jammulinksnews.com
What are the latest earnings results for Protalix BioTherapeutics Inc.Breakout Stocks Ideas For 2025 - jammulinksnews.com
Protalix BioTherapeutics Inc. stock momentum explainedYearly Trend Summary and Opportunity Breakdown - Newser
Advanced analytics toolkit walkthrough for Protalix BioTherapeutics Inc.Investment Roadmap for High Potential Stocks - Newser
Why Protalix BioTherapeutics Inc. stock attracts strong analyst attentionReliable Setup Screener with Low Risk - Newser
What makes Protalix BioTherapeutics Inc. stock price move sharplyFree Stock Selection With High Accuracy - Newser
How institutional ownership impacts Protalix BioTherapeutics Inc. stockSecure Buy Strategy Based on Risk Parameters - Newser
Published on: 2025-07-31 03:35:16 - Newser
How Protalix BioTherapeutics Inc. stock reacts to Fed policy changesPredictive Screener for Daily Trade Watch - Newser
Is Protalix BioTherapeutics Inc. a Top Dividend Stock to Watch in 2025Entry Zone Watchlist With Momentum Focus - Newser
Plant Derived Proteins Market Driven by Protalix to Novo Nordisk, Poised for Robust Expansion - FMIBlog
Protalix BioTherapeutics Inc. At Decision Level — Rebound or ResistanceWeekly Stock Watch With Growth Focus Expanded - beatles.ru
Is Protalix BioTherapeutics Inc. Forming a Consolidation BaseShort Term Setup With Predictive Chart Confirmed - metal.it
Key External Factors That Drive Protalix BioTherapeutics Inc. Stock Price MovementsGrowth Projection Summary for Long-Term Investors - Newser
Published on: 2025-07-29 01:26:29 - metal.it
Is Protalix BioTherapeutics Inc. stock overvalued or undervaluedCapitalize on fast-moving stock opportunities - jammulinksnews.com
Published on: 2025-07-27 22:47:19 - jammulinksnews.com
When is Protalix BioTherapeutics Inc. stock expected to show significant growthTremendous return rates - jammulinksnews.com
What analysts say about Protalix BioTherapeutics Inc. stockUnprecedented profit potential - PrintWeekIndia
What drives Protalix BioTherapeutics Inc. stock priceHigh-yield trading alerts - Autocar Professional
What makes Protalix BioTherapeutics Inc. stock attractive to long term investorsFree Predictions - jammulinksnews.com
How Protalix BioTherapeutics Inc. stock performs during market volatilityTrend Based Entry Alerts - Newser
Is Protalix BioTherapeutics Inc. a good long term investmentFree Wealth Management Insights - Autocar Professional
Protalix BioTherapeutics Inc. Stock Analysis and ForecastMassive wealth growth - Autocar Professional
Protalix Appoints New CFO to Boost Growth Strategy - The Globe and Mail
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):